Collegium Pharmaceutical Reports Strong Q1 2026 Results and Reaffirms Full-Year Guidance

summarizeSummary

Collegium Pharmaceutical announced strong Q1 2026 financial results with significant year-over-year growth in revenue and net income, reaffirmed its full-year guidance, and provided a positive update on the accretive AZSTARYS acquisition.

check_boxKey Events

• Strong Q1 2026 Financial Performance

  Product revenues, net increased 9% year-over-year to $193.5 million. GAAP net income rose significantly to $14.5 million from $2.4 million in Q1 2025, with diluted GAAP EPS at $0.40 compared to $0.07. Adjusted EBITDA also grew 9% to $103.9 million.

• Reaffirmed Full-Year 2026 Guidance

  The company reaffirmed its full-year 2026 guidance for Product Revenues, Net ($805 - $825 million), JORNAY PM Revenue, Net ($190 - $200 million), and Adjusted EBITDA ($455 - $475 million) for its current business, with an update expected post-AZSTARYS acquisition close.

• AZSTARYS Acquisition Update

  The acquisition of AZSTARYS for $650 million in cash, with potential additional milestones up to $135 million, is on track to close in Q2 2026. It is expected to be immediately accretive to adjusted EBITDA and extend revenues into the late 2030s, strengthening the ADHD portfolio.

auto_awesomeAnalysis

Collegium Pharmaceutical delivered robust first-quarter results, exceeding prior-year performance across key financial metrics. The company reported a significant increase in GAAP net income and diluted EPS, alongside strong revenue growth for both its JORNAY PM and pain portfolios. The reaffirmation of full-year 2026 guidance for the current business, notably excluding the impact of the planned AZSTARYS acquisition, signals confidence in ongoing operations. The update on the AZSTARYS acquisition, expected to close in Q2 2026 and be immediately accretive to adjusted EBITDA, reinforces the company's strategic growth trajectory and diversification efforts.